JULIE EPPLE: Open Payments
NPI 1043242183 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,000 in 57 payments from 15 companies in 2025. Trend: 2023 $952 · 2024 $1,338 · 2025 $1,000
Food & beverage: $1,000
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $329 |
| PFIZER INC. | 9 | $141 |
| AstraZeneca Pharmaceuticals LP | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Exact Sciences Corporation | 3 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $42 |
| Amgen Inc. | 2 | $37 |
| Novo Nordisk Inc | 2 | $33 |
| GlaxoSmithKline, LLC. | 2 | $32 |
Products named: VRAYLAR, QULIPTA, NURTEC ODT, CAPLYTA, UBRELVY, GEMTESA, AIRSUPRA, XIFAXAN.
Industry payments across MO — which companies pay providers there.
